The impairment losses in the Crop Science division negatively affected Bayer's overall earnings, which is a concern for investors. However, the strong sales performance in the Pharmaceutical division, particularly from Nubeqa and Kerendia, provides a positive offset. This mixed result suggests a neutral short-term impact on Bayer's stock price.